- Home
- NMRA vs AMRN Comparison
NMRA vs AMRN Comparison
Compare NMRA & AMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NMRA | AMRN |
|---|---|---|
| Founded | 2019 | 1989 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 311.3M | 342.8M |
| IPO Year | 2023 | 1998 |
Fundamental Metrics
Financial Performance| Metric | NMRA | AMRN |
|---|---|---|
| Price | $1.63 | $14.36 |
| Analyst Decision | Buy | Strong Sell |
| Analyst Count | 8 | 1 |
| Target Price | $7.50 | ★ $12.00 |
| AVG Volume (30 Days) | ★ 685.8K | 54.5K |
| Earning Date | 05-07-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 5.23 | ★ 55.00 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $181,104,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1.26 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 39.22 |
| 52 Week Low | $0.83 | $12.96 |
| 52 Week High | $3.65 | $20.90 |
Technical Indicators
Market Signals| Indicator | NMRA | AMRN |
|---|---|---|
| Relative Strength Index (RSI) | 50.88 | 46.56 |
| Support Level | $1.50 | $14.18 |
| Resistance Level | $1.72 | $14.49 |
| Average True Range (ATR) | 0.09 | 0.51 |
| MACD | 0.01 | 0.08 |
| Stochastic Oscillator | 72.00 | 69.91 |
Price Performance
Historical ComparisonAbout NMRA Neumora Therapeutics Inc.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.
About AMRN Amarin Corporation plc
Amarin Corp PLC is a pharmaceutical company. The company is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa. The company focuses on treatments to stop cardiovascular disease causing death, by providing patients, doctors and investors with reliable cardiovascular treatment options. Geographically, the company derives maximum revenue from United States.